AR045841A1 - Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla. - Google Patents

Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.

Info

Publication number
AR045841A1
AR045841A1 ARP040103504A ARP040103504A AR045841A1 AR 045841 A1 AR045841 A1 AR 045841A1 AR P040103504 A ARP040103504 A AR P040103504A AR P040103504 A ARP040103504 A AR P040103504A AR 045841 A1 AR045841 A1 AR 045841A1
Authority
AR
Argentina
Prior art keywords
tiazolil
methyl
tetraazatridecan
dioxo
bis
Prior art date
Application number
ARP040103504A
Other languages
English (en)
Original Assignee
Richmond Sa Com Ind Y Financie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richmond Sa Com Ind Y Financie filed Critical Richmond Sa Com Ind Y Financie
Priority to ARP040103504A priority Critical patent/AR045841A1/es
Priority to PCT/ES2005/000524 priority patent/WO2006037827A1/es
Priority to PT05799880T priority patent/PT1800681E/pt
Priority to ES05799880T priority patent/ES2390136T3/es
Priority to MX2007003431A priority patent/MX2007003431A/es
Priority to BRPI0515293-3A priority patent/BRPI0515293A/pt
Priority to EP05799880A priority patent/EP1800681B1/en
Publication of AR045841A1 publication Critical patent/AR045841A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Abstract

Una composición farmacéutica sólida que comprende al tiazolil metil éster del ácido [5S-(5R*,8R*,10R*,11R*)]-10-hidroxi-2-metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12-tetraazatridecan-13-oico (Ritonavir) y un compuesto que permite la penetración del fluido gastrointestinal en dicha composición, el cual se selecciona entre el grupo que comprende los silicatos y el óxido de sílice, y un procedimiento para la elaboración de esta composición, que comprende una etapa de amasado en la cual se controla estrictamente la velocidad y el tiempo de agregado del solvente. Dicha composición en combinación con otra sustancia terapéuticamente activa.
ARP040103504A 2004-09-28 2004-09-28 Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla. AR045841A1 (es)

Priority Applications (7)

Application Number Priority Date Filing Date Title
ARP040103504A AR045841A1 (es) 2004-09-28 2004-09-28 Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
PCT/ES2005/000524 WO2006037827A1 (es) 2004-09-28 2005-09-28 Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*,8r*,10r*,11r*)]-10 hidroxi-2-metil-5-(1-metiletil)-1-[2-(1-metiletil)-4­ tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12­ tetraazatridecan-13-oico y un procedimiento para prepararla
PT05799880T PT1800681E (pt) 2004-09-28 2005-09-28 Composição farmacêutica sólida compreendendo o éster de tiazolilmetilo do ácido [5s-(5r*,8r*,10r*,11r*)]-10- hidroxi-2-metil-5-(1-metiletil)-1-[2-(1-metiletil)-4- tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico e processo
ES05799880T ES2390136T3 (es) 2004-09-28 2005-09-28 Una composición farmacéutica sólida que comprende al tiazolil metil ester del ácido [5S-(5R*,8R,10R*,11R*)]-10-hidroxi-2-metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12-tetraazatridecan-13-oico y a un procedimiento para prepararla
MX2007003431A MX2007003431A (es) 2004-09-28 2005-09-28 Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r,*8r*,10r*,11r*)]-10-hidroxi-2-metil- 5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis (fenilmetil)-2,4,7,12-tetraazatridecan-13-oico y un pro
BRPI0515293-3A BRPI0515293A (pt) 2004-09-28 2005-09-28 composição farmacêutica sólida que compreende o tiazolil metil éster do ácido [5s-(5r*,8r*,10r*,11r*)]-10-hidroxi-2-metil-5-(1-metiletil)- 1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis (fenilmetil)-2,4,7,12-tetraazatridecan-13-óico e um procedimento para prepará-la
EP05799880A EP1800681B1 (en) 2004-09-28 2005-09-28 Solid pharmaceutical composition comprising the thiazolyl methyl ester of [5s-(5r*,8r*,10r*,11r*)]-10-hydroxy-2-methyl-5-(1-methylethyl)-1-[2-1(1-methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-2,4,7,12-tetraazatridecan-13-oic acid and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP040103504A AR045841A1 (es) 2004-09-28 2004-09-28 Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.

Publications (1)

Publication Number Publication Date
AR045841A1 true AR045841A1 (es) 2005-11-16

Family

ID=36142313

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103504A AR045841A1 (es) 2004-09-28 2004-09-28 Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.

Country Status (7)

Country Link
EP (1) EP1800681B1 (es)
AR (1) AR045841A1 (es)
BR (1) BRPI0515293A (es)
ES (1) ES2390136T3 (es)
MX (1) MX2007003431A (es)
PT (1) PT1800681E (es)
WO (1) WO2006037827A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029866T2 (en) 2007-02-23 2017-03-28 Gilead Sciences Inc Modulation of pharmacokinetic parameters of therapeutic agents
EP2178513B1 (en) * 2007-06-22 2011-03-30 Bristol-Myers Squibb Company Tableted compositions containing atazanavir
US20100183715A1 (en) * 2007-06-22 2010-07-22 Bristo-Meyers Squibb Company Tableted compositions containing atazanavir
KR101784647B1 (ko) 2008-05-02 2017-10-11 길리애드 사이언시즈, 인코포레이티드 제약 제제의 가공성 향상을 위한 고체 담체 입자의 용도
EP2391350A1 (en) 2008-12-18 2011-12-07 Ranbaxy Laboratories Limited Atazanavir formulations
WO2013057469A1 (en) * 2011-10-20 2013-04-25 Cipla Limited Pharmaceutical antiretroviral compositions
CA2918707A1 (en) * 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264020B (it) * 1993-01-28 1996-09-09 Recordati Chem Pharm Procedimento per la preparazione di microgranuli idonei alla sospensione in liquidi
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions
US6147095A (en) * 1998-11-04 2000-11-14 Pharmacia & Upjohn Company Method for improving the pharmacokinetics of tipranavir
US7205413B2 (en) * 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
JP2006056781A (ja) * 2002-11-15 2006-03-02 Bioserentack Co Ltd 界面活性剤を含む固形化製剤
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation

Also Published As

Publication number Publication date
ES2390136T3 (es) 2012-11-07
EP1800681B1 (en) 2012-06-27
WO2006037827A1 (es) 2006-04-13
EP1800681A1 (en) 2007-06-27
MX2007003431A (es) 2007-08-06
BRPI0515293A (pt) 2008-07-15
PT1800681E (pt) 2012-10-03

Similar Documents

Publication Publication Date Title
ES2328559T3 (es) Uso de ritonavir (abt-538) para mejorar la farmacocinetica de farmacosmetabolizados por citocromo p450 en un metodo de tratamiento del sida.
PE20110019A1 (es) Composicion farmaceutica que contiene un sensibilizante de insulina y un secretagogo de insulina
EA200970726A1 (ru) Твердый препарат, содержащий алоглиптин и пиоглитазон
AR054238A1 (es) Composicion farmaceutica que contiene una biguanida y un derivado de tiazolidindiona
BRPI0716171A8 (pt) Composto, composição farmacêutica e uso de um composto
UY30099A1 (es) Una composicion solida de taxano liofilizado, un procedimiento para preparar dicha composicion solida, una formulacion farmacéutica y un conjunto (kit) para la preparacion de una formulacion inyectable de taxano
BRPI0515293A (pt) composição farmacêutica sólida que compreende o tiazolil metil éster do ácido [5s-(5r*,8r*,10r*,11r*)]-10-hidroxi-2-metil-5-(1-metiletil)- 1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis (fenilmetil)-2,4,7,12-tetraazatridecan-13-óico e um procedimento para prepará-la
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
AR051340A1 (es) Compuesto de c(4)- metoximetil acil pirrolidina, su uso para preparar un medicamento, formulacion farmaceutica que lo comprende y proceso para prepararlo
EA201170527A1 (ru) Фармацевтические композиции, включающие соединения бороновой кислоты
CL2012002126A1 (es) Composicion farmaceutica topica que comprende 1`-{[5-(trifluorometil)furan-2-il]metil}espiro[furo[2,3-f][1,3]benzodioxol-7,3`-indol]-2`(1`h)-ona; y uso para tratar, una enfermedad o condicion tal como dolor neuropatico, dolor quirurgico, dolor por trauma, dolor de cabeza cronico, entre otras.
RU2013148119A (ru) Лиофилизированный препарат ботулотоксина
BRPI0517701A (pt) uso de um composto na preparação de medicamentos para o tratamento de diabetes mellitus
CO6480980A2 (es) Composicion farmaceutica para un inhibidor de proteasa del virus de la hepatitis c
WO2008000731A3 (en) Pharmaceutical composition for the oral administration of omega polyenoic fatty acids
CL2007003711A1 (es) Composicion farmaceutica liquida transdermica que comprende un primer y segundo mejorador de la penetracion dermica, un solvente primario aprotico y una cantidad efectiva de flunixina o una sal farmaceuticamente aceptable de la misma; y uso para el t
US20230248712A1 (en) Methods and compositions for treating rna viral infections
AR051797A1 (es) Derivados de hidantoina inhibidores de metaloproteinasas
RU2017117559A (ru) Бензопроизводные с шестичленным кольцом в качестве ингибитора dpp-4 и их применение
WO2008070350A3 (en) Methods and compositions related to wrapping of dehydrons
EA200601901A1 (ru) Композиции, содержащие иммуномодулирующие соединения для лечения и управления течением миелодиспластических синдромов и способы с их использованием
RU2016136327A (ru) Композиции на основе мелатонина для парентерального введения
NO20082181L (no) Formuleringer av Fispemifen
UY29069A1 (es) Uso de compuestos tpo miméticos y composiciones farmacéuticas para el tratamiento de la anemia
WO2007124700A3 (en) Pharmaceutical composition containing taxane derivative destined for the preparation of an infusion solution, method of preparation thereof and use thereof